1	Shared genetic basis informs the roles of polyunsaturated
2	fatty acids in brain disorders
3	Huifang Xu ^{1*} , Yitang Sun ^{1*} , Michael Francis ² , Claire F. Cheng ¹ , Nitya T.R. Modulla ¹ , J. Thomas
4	Brenna ^{3,4,5} , Charleston W. K. Chiang ^{6,7} , <u>Kaixiong Ye</u> ^{1,2#}
5	¹ Department of Genetics, University of Georgia, Athens, Georgia;
6	² Institute of Bioinformatics, University of Georgia, Athens, Georgia;
7	³ Dell Pediatric Research Institute and Department of Pediatrics, The University of Texas at
8	Austin, Texas;
9	⁴ Dell Pediatric Research Institute and Department of Chemistry, The University of Texas at
10	Austin, Texas;
11	⁵ Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at
12	Austin, Texas;
13	⁶ Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck
14	School of Medicine, University of Southern California, Los Angeles, California;
15	⁷ Department of Quantitative and Computational Biology, University of Southern California, Los
16	Angeles, California;
17	
18	*Co-first authors

19 [#]Corresponding author: kaixiong.ye@uga.edu

20 Abstract

21 The neural tissue is rich in polyunsaturated fatty acids (PUFAs), components that are 22 indispensable for the proper functioning of neurons, such as neurotransmission. PUFA nutritional 23 deficiency and imbalance have been linked to a variety of chronic brain disorders, including 24 major depressive disorder (MDD), anxiety, and anorexia. However, the effects of PUFAs on 25 brain disorders remain inconclusive, and the extent of their shared genetic determinants is largely 26 unknown. Here, we used genome-wide association summary statistics to systematically examine 27 the shared genetic basis between six phenotypes of circulating PUFAs (N = 114,999) and 20 28 brain disorders (N = 9,725-762,917), infer their potential causal relationships, identify 29 colocalized regions, and pinpoint shared genetic variants. Genetic correlation and polygenic 30 overlap analyses revealed a widespread shared genetic basis for 77 trait pairs between six PUFA 31 phenotypes and 16 brain disorders. Two-sample Mendelian randomization analysis indicated 32 potential causal relationships for 16 pairs of PUFAs and brain disorders, including alcohol 33 consumption, bipolar disorder (BIP), and MDD. Colocalization analysis identified 40 shared loci 34 (13 unique) among six PUFAs and ten brain disorders. Twenty-two unique variants were 35 statistically inferred as candidate shared causal variants, including rs1260326 (GCKR), rs174564 36 (FADS2) and rs4818766 (ADARB1). These findings reveal a widespread shared genetic basis 37 between PUFAs and brain disorders, pinpoint specific shared variants, and provide support for 38 the potential effects of PUFAs on certain brain disorders, especially MDD, BIP, and alcohol 39 consumption.

40 Introduction

41 Disorders of the brain contribute significantly to the global disease burden [1, 2]. For 42 example, in 2019, more than 970 million individuals suffered from 12 mental disorders, ranging 43 from 13.6 million for eating disorders to 301.4 million for anxiety disorders [2]. These disorders 44 encompass a wide range of psychiatric and neurological symptoms, including cognitive 45 impairment, emotional dysregulation, and behavioral disturbances, all of which profoundly 46 disrupt the life of the patients, and can in severe cases lead to suicide [3]. Effective prevention 47 and treatment of brain disorders are of utmost importance in improving clinical symptoms and 48 overall quality of life. One promising and emerging therapeutic approach is nutritional medicine 49 [4], which seeks to prevent the onset of brain disorders or alleviate their clinical manifestations 50 by implementing specific nutritional interventions [4, 5].

51 Brain structural lipids are rich in long-chain omega-3 and omega-6 polyunsaturated fatty 52 acids (PUFAs) [6]. Dietary deficiency of omega-3 PUFAs leads to global deficits in neural 53 function in experimental animals [7]. In humans, PUFAs and particularly omega-3s, have been 54 suggested to have protective and therapeutic effects on brain disorders because they regulate 55 physiological processes such as neuroinflammation, neurotransmission, and neuron survival [4, 6, 56 8]. Omega-3 supplementation has shown promising results in reducing clinical symptoms 57 associated with a range of brain conditions, including MDD [9, 10], anxiety disorders [11], 58 schizophrenia [12, 13], attention-deficit/hyperactivity disorder (ADHD) [14], autism spectrum 59 disorder [15] and Alzheimer's disease (ALZ) [16]. However, several randomized controlled trials 60 reported small or no effects of PUFAs on schizophrenia [5], depression [17], ALZ [18] and 61 psychosis [19, 20]. Consequently, the overall impact of PUFAs on human brain disorders 62 remains inconclusive, necessitating further investigation to establish their therapeutic potential.

63 While observational associations are commonly confounded by unknown or unmeasured 64 factors [21], exploring the shared genetic basis between PUFAs and brain disorders offers 65 valuable insights into their shared biological pathways and potential causal relationships [22]. 66 Previous studies have leveraged genetic information to investigate the connections between 67 PUFAs and brain disorders (Supplementary Table S1), such as the application of Mendelian 68 randomization (MR) to statistically infer causal relationships. For instance, a recent MR study 69 suggested that decreased docosahexaenoic acid (DHA) and increased omega-6 to omega-3 ratio 70 have causal links with MDD, and it further identified the fatty acid desaturase (FADS) gene 71 cluster as a common genetic signal [23]. In an experimental study, mice with Fads1/2 genes 72 knockout were used to simulate the effect of BIP risk allele on Fads 1/2 activity, revealing 73 significant changes in lipid profile and behavioral alterations [24]. However, current genetic 74 studies primarily concentrate on specific brain disorders (e.g., MDD [23, 25], SCZ [26, 27], and 75 BIP [24, 28]) or a limited number of genes, such as FADS [23, 24, 26, 28] and ELOVL2/5 [26]. 76 Therefore, it is necessary to explore the broader genomic landscape to ascertain additional 77 genetic determinants that underlie the connection between PUFAs and brain disorders.

78 Our study aims to systematically explore the shared genetic basis between the levels of 79 circulating PUFAs (cPUFAs) and brain disorders, infer their potential causal relationships, 80 identify shared genomic regions, and pinpoint specific shared genetic variants. We performed 81 four major analyses using genome-wide association study (GWAS) summary statistics for six 82 cPUFA phenotypes (N = 114,999) and 20 brain disorders (N = 9,725-762,917). First, we 83 estimated genetic correlation, and second, quantified the number of shared genetic variants, 84 between cPUFA phenotypes and brain disorders. Third, we performed MR analysis to 85 statistically infer causal associations between cPUFAs and brain disorders. Lastly, we conducted

- 86 colocalization analysis and statistical fine-mapping to identify colocalized regions and pinpoint
- 87 putative shared causal variants. Collectively, our study characterizes the shared genetic basis and
- 88 informs the relationships between cPUFAs and brain disorders.

89 Methods

90 GWAS summary statistics and preprocessing

91 Six cPUFA phenotypes and 20 brain disorders were included in the study 92 (Supplementary Figure S1; Supplementary Table S2). The six cPUFA traits were the relative 93 percentages of total PUFAs, omega-3, omega-6, DHA, and linoleic acid (LA) in total fatty acids, 94 and the omega-6 to omega-3 ratio. They are abbreviated as PUFA%, omega-3%, omega-6%, DHA%, LA%, and omega-6:omega-3, respectively. The 20 brain disorders included 95 96 schizophrenia (SCZ) [29], MDD [30], BIP [31], obsessive-compulsive disorder (OCD) [32], 97 anxiety disorders and factors (ANX) [33], post-traumatic stress disorder (PTSD) [34], anorexia 98 nervosa (AN) [35], autism spectrum disorder (ASD) [36], Tourette syndrome (TS) [37], attention 99 deficit-hyperactivity disorder (ADHD) [38], mood disorders (MOOD), insomnia (INS) [39], 100 neuroticism (NE) [40], ALZ [41], opioid dependence (OD) [42], cannabis use disorder (CUD) 101 [43], alcohol dependence (AD) [44], alcohol use disorder identification test total score 102 (AUDIT T), AUDIT focusing on alcohol consumption (AUDIT C) and AUDIT focusing on the 103 problematic consequences of drinking (AUDIT P) [45].

104 Publicly available GWAS summary statistics of all cPUFAs and brain disorders were 105 downloaded from IEU Open GWAS [46] and Psychiatric Genomic Consortium (PGC) [47]. 106 GWAS summary statistics for insomnia [39] were downloaded from the Center for 107 Nutrigenomics and Cognitive Research (CNCR, https://ctg.cncr.nl/software/summary statistics). 108 Multiple GWAS for each of seven brain disorders (i.e., SCZ, BIP, MDD, INS, ALZ, AN, ASD) 109 were included for replication analysis (Supplementary Table S2). A total of 34 GWAS for brain 110 disorders and 11 GWAS for cPUFAs were examined. Four GWAS were removed from our study 111 for reasons including 1) no clear information indicating effect allele (n=2) [48, 49]; 2) incorrect

data format (n=1) [50]; 3) the number of cases is less than 1000 (n=1) [51]. We focused on
European ancestry to align ancestry across studies. Phenotypes associated with alcohol intake
(AD, AUDIT_T, AUDIT_C, AUDIT_P) had pairwise genetic correlations less than 1 [45], and
therefore were analyzed separately.

116 All GWAS summary statistics were harmonized to ensure data quality and consistency. 117 Summary statistics of three GWAS from hg18 reference genome build were converted into 118 hg19/GRCh37 genome build by Liftover [52]. MungeSumstats (v1.3.17) [53] was used to 119 harmonize all GWAS summary statistics including: 1) uniformity in strand designation; 2) 120 uniformity in SNP ID; 3) same effect allele; 4) effect size and standard error, or Z score are 121 included; 5) hg19/GRCh37 reference genome build is used; 6) uniformity in the p-value format; 122 7) removal of InDels; 8) removal of SNPs with low genotype imputation quality (INFO < 0.3). 123 After harmonization, a total of 10,568,861 SNPs for six cPUFAs and 1,147,602 to 14,124,455 124 SNPs for 20 brain disorders were included in the downstream analysis (Supplementary Table 125 **S2**). For each trait, we mainly focused on the GWAS with the largest sample size, and the rest 126 were presented in supplementary results.

127 Estimation of SNP-based heritability (h²_{SNP}) and pairwise genetic correlation (r_g)

Linkage Disequilibrium Score regression (LDSC, v1.0.1) [54] was applied to estimate SNP-based heritability (h_{SNP}^2) for each phenotype using GWAS summary statistics. For casecontrol traits, h_{SNP}^2 was converted to the liability-scale by considering the disease prevalence and sample proportion (**Supplementary Table S2**). For quantitative traits, the observed-scale heritability was estimated.

133 Cross-trait LDSC [55] was used to compute pairwise genetic correlations (r_g) using 134 GWAS summary statistics between six cPUFAs and 20 brain disorders. Pre-computed reference

135 panel LD score of European samples in the 1000 Genomes Project (1KGP) phase 3 [56] was 136 downloaded from https://data.broadinstitute.org/alkesgroup/LDSCORE/eur w ld chr.tar.bz2. 137 SNP-based heritability and pairwise genetic correlation analyses were run using Hapmap3 SNPs 138 with imputation INFO > 0.9 and minor allele frequency (MAF) > 1%. SNPs in the major 139 histocompatibility complex (MHC) region were excluded. P-value cutoffs of 0.05, 0.001, and 140 0.05 divided by the number of tests (i.e., the Bonferroni-corrected threshold) were used to 141 represent different levels of statistical significance. Genetic correlation coefficients and p-values 142 were visualized using the R corrplot (v0.92) package [57].

143 Estimation of polygenicity

To estimate the number of common variants that are associated with cPUFAs or brain 144 145 disorders, a univariate Gaussian mixture model in MiXeR [58] was applied to the GWAS 146 summary statistics. We restricted the univariate analysis to 19 brain disorder GWAS 147 (corresponding to 15 unique phenotypes) with N > 46,000 to ensure statistical power. Five 148 GWAS for ANX, OCD, TS, OD, AD had small sample sizes and were not included in the analysis. Pre-computed EUR reference panel LD score was used as in the LDSC analysis. To 149 150 ensure compatibility with MiXeR, we utilized the munge_sumstats.py script provided by MiXeR 151 to further process GWAS summary statistics. This step was necessary to meet the specific 152 requirements of MiXeR, particularly addressing the sample imbalance in case-control phenotypes by utilizing the effective sample size $(N_{eff} = \frac{4}{\frac{1}{Ncase} + \frac{1}{Ncase}})$. Additionally, we 153 obtained information on allelic LD r^2 correlations and allele frequency in the 1KGP European 154 155 samples from the MiXeR GitHub repository. MiXeR provides a reference set of about 11 million SNPs, which is used to estimate the number of trait-associated variants that explain 90% of h^2_{SNP} . 156

157 Quantification of polygenic overlap between cPUFAs and brain disorders

158 The MiXeR bivariate causal mixture model [59] was applied to quantify the number of 159 variants that have nonzero effects on both traits (nc_{12}) . We performed cross-trait analyses to 160 estimate polygenic overlap between cPUFAs and brain disorders, including six GWAS for six 161 cPUFAs and 19 GWAS for 15 brain disorders. The bivariate analysis provides the proportion 162 (π_{12}) , number (nc_{12}) , and correlation of effect size within the shared polygenic components (ρ_{12}) . 163 We calculated Z-statistics using the formula $Z = \beta/SE$ and visualized the effect sizes of all 164 SNPs in pairs of GWAS summary statistics using the R hexbin (v1.28.2) package. We used R 165 ComplexHeatmap (v2.14.0) [60] package to visualize the number of shared variants between 166 cPUFAs and brain disorders.

167 Mendelian randomization

168 MR is a method in genetic epidemiology that uses SNPs as genetic instruments to statistically infer causal associations between exposures and outcomes [61]. SNPs were 169 170 identified as being significantly associated with each exposure at the genome-wide significance level ($P < 5 \times 10^{-8}$), and independent SNPs were derived using LD clumping ($r^2 < 0.001$ within a 171 172 10,000 kb window). For the primary analysis, the potential causal effects were estimated using a 173 multiplicative random-effect inverse weighted variance (IVW) model [62]. The MR-Egger 174 method was applied to detect and correct for possible pleiotropy, while a p-value > 0.05 in its 175 intercept test was used to rule out the presence of horizontal pleiotropic effects [63]. We also 176 used weighted median and weighted mode approaches to explore the robustness of our findings 177 in the presence of potential pleiotropy [64, 65]. As an additional sensitivity analysis against 178 pleiotropy, the MR-PRESSO method was performed to evaluate overall horizontal pleiotropy 179 and to re-calculate effect estimates after removing outlier SNPs [66]. A threshold of F-statistics >

10 indicates strong genetic instruments. Cochran Q-statistic was calculated to quantify the 181 heterogeneity among SNPs [67, 68]. Scatter plots, forest plots, and leave-one-out plots were 182 generated to visualize the effects of individual genetic instruments. To adjust for multiple testing, 183 we utilized the false-discovery rate (FDR) approach [69]. All analyses were performed using the 184 TwoSampleMR (v0.5.6) and MR-PRESSO (v1.0) packages in R [66, 70].

185 **Colocalization analysis**

We assessed the colocalization of genetic associations across traits using HyPrColoc 186 187 (v1.0) [71]. First, pairwise colocalization analyses were conducted for each pair of cPUFA and 188 brain disorder. We further performed multi-trait colocalization analysis for all cPUFAs and brain 189 disorders. We used the default prior probability that an SNP is associated with a single trait (P = 1×10^{-4}) and a conditional prior probability that an SNP is associated with an additional trait 190 191 given that it is already associated with another trait ($P_c = 0.02$). We defined a significant colocalized region as a posterior probability (PP) > 0.7. Regional association plots and 192 193 colocalization probability plots were generated with gassocplot (v0.14.0) R package, and LD 194 information was from 1KGP.

195 Genome-wide statistical fine-mapping

To statistically infer genetic variants that are causally associated with cPUFAs and brain disorders, we performed genome-wide statistical fine-mapping with GWAS summary statistics using SuSiE (v0.12.27). We first defined significant loci for each GWAS. Each significant locus was determined as a region spanning 500kb above and below a top significant SNP ($P < 5 \times 10^{-8}$). After defining one locus, we eliminated this locus, searched for the most significant SNP in the remaining dataset, and defined the next locus. We iterated this process until no additional

202 significant locus was found. Note that some loci overlap with each other, and the inclusion of LD 203 information in the overlapped region is sometimes necessary for accurate fine-mapping. Since 204 samples of all cPUFA phenotypes and some brain disorders were obtained from UK Biobank, we 205 used LD matrices calculated based on 337,000 British-ancestry individuals in UK Biobank 206 (UKBB-LD) [72]. All LD matrices files downloaded from were 207 https://labs.icahn.mssm.edu/minervalab/resources/data-ark/ukbb_ld/. We extracted pairwise 208 allelic LD correlations (r) for all SNPs in each defined locus. We summarized and reported 95% 209 credible sets (CS) of all significant loci. Additionally, we identified SNPs within the CS of the 210 cPUFAs and brain disorders dataset, which exhibited a posterior probability greater than 0.5 in at 211 least one dataset.

212 Functional annotation and gene set enrichment analysis

To assess the functional consequences of the potentially causal variants prioritized by HyPrColoc and SuSiE, we used the Ensembl Variant Effect Predictor (VEP) [73] for functional annotation, including their nearby genes, variant type and consequence, allele frequency in the IKGP European sample, pathogenicity, and related phenotypes. Gene set enrichment analysis was conducted for candidate genes using the FUMA [74] GENE2FUNC module. GTEx v8 RNA-seq data [75] was used to examine tissue-specific expression patterns of candidate genes.

- 219 Data and code availability
- All GWAS summary statistics are publicly available as described above. All the code for
 this study was uploaded to GitHub for public access (<u>https://github.com/Huifang-Xu/PUFA-BD</u>).

222 **Results**

223 Widespread, moderate genetic correlations between cPUFAs and brain disorders

224 Genetic correlations (r_{o}) between cPUFA phenotypes and brain disorders were estimated 225 using LDSC. Consistent with previous studies, there were strong genetic correlations between 226 cPUFAs [76] and between brain disorders [77-80] (Supplementary Figure S2). Widespread and 227 moderate genetic correlations were observed between 16 brain disorders and six cPUFA relative 228 measures, including PUFA%, omega-6%, LA%, omega-3%, DHA% and the omega-6:omega-3 229 ratio (Figure 1A, Supplementary Figure S3 and Supplementary Table S3). Out of the total 230 120 pairs, 77 pairs (64.2%) had P < 0.05 (average $|r_g| = 0.19$), 43 pairs (35.8%) had P < 0.001231 (average $|r_g| = 0.23$), and 34 pairs (28.3%) showed significant genetic correlations after Bonferroni correction ($P < 4.17 \times 10^{-4}$, average $|\mathbf{r}_g| = 0.22$). Over 60% of the significant pairs 232 (48/77 pairs with P < 0.05 and 22/34 pairs with $P < 4.17 \times 10^{-4}$) showed negative correlations 233 234 between cPUFAs and brain disorders, suggesting that the shared genetic determinants are 235 associated with higher cPUFA levels but with reduced risks of brain disorders, such as NE and 236 PUFA% (Figure 1C).

PUFA%, omega-6%, omega-3%, LA%, and DHA% have significant negative correlation with the following brain disorders, including the three substance use disorders (OD: $r_g = -0.23 \sim -$ 0.40, P < 0.05; AD: $r_g = -0.18 \sim -0.30$, P < 0.05; and CUD: $r_g = -0.20 \sim -0.27$, $P < 3 \times 10^{-4}$), ADHD ($r_g = -0.22 \sim -0.33$, $P < 6.72 \times 10^{-6}$), PTSD ($r_g = -0.16 \sim -0.32$, P < 0.05), ANX ($r_g = -$ 0.22, P < 0.05), INS ($r_g = -0.12 \sim -0.20$, $P < 9 \times 10^{-4}$), MDD ($r_g = -0.10 \sim -0.19$, P < 0.05), and NE ($r_g = -0.08 \sim -0.14$, P < 0.01; **Figure 1A and Supplementary Table S3**). In contrast, these cPUFA measures are positively correlated with two disorders with compulsive behaviors (OCD:

r_g = 0.14 ~ 0.30, P < 0.05; AN: r_g = 0.16 ~ 0.27, $P < 6.50 \times 10^{-5}$). We did not observe any significant genetic correlations between any cPUFAs and ALZ, MOOD, ASD, or TS, suggesting that they share only a small proportion of common genetic components, or that the genetic components they share have mixed effects on the two traits. It can also be partially explained by insufficient statistical power due to small sample sizes of the GWAS of MOOD (N_{case} = 1,546) and TS (N_{case} = 4,819).

250 Widespread, moderate polygenic overlap between cPUFAs and brain disorders

To quantify the polygenicity of and polygenic overlap between cPUFAs and brain disorders, we applied the MiXeR univariate and bivariate Gaussian mixture models, respectively, to their GWAS summary statistics. MiXeR statistically estimates the number of causal variants needed to explain 90% of the SNP heritability of a trait without explicitly identifying the specific variants. It also quantifies the number of shared causal variants between two traits (nc_{12}), irrespective of their genetic correlation [59]. Five brain disorders (i.e., TS, OCD, ANX, OD and AD) were not included in this analysis due to insufficient sample sizes.

258 All pairs of cPUFAs and brain disorders were statistically inferred to share causal variants, 259 although the degrees of sharing differ (Figure 1B, Supplementary Figure S4 and 260 Supplementary Table S4). They ranged from five variants between omega-3% and ALZ to 361 261 between PUFA% and MDD. PUFA% shared the greatest number of common variants ($nc_{12} = 37$ -262 361) with brain disorders, while omega-3% shared the least number of common variants ($nc_{12} =$ 263 5-33). Consistent with the findings of genetic correlation, 10 brain disorders (MDD, CUD, AN, 264 ADHD, NE, INS, SCZ, PTSD, AUDIT_C, and AUDIT_T) have strong polygenic overlaps with multiple cPUFAs. For instance, PUFA% and NE have a strong negative genetic correlation ($r_g = -$ 265 0.13, $P = 2.0 \times 10^{-4}$) and a high level of polygenic overlap (nc₁₂ = 348; Figure 1C), indicating 266

267 that most of the common variants shared between PUFA% and NE have opposite effect signs. 268 ALZ and cPUFAs share very low numbers of common variants. Interestingly, for some pairs of 269 cPUFAs and brain disorders, we observed no significant genetic correlations; however, they have 270 strong polygenic overlap, implying the presence of mixed effect directions among shared genetic 271 variants. For example, LA% does not have significant genetic correlation with AUDIT_C ($r_g =$ 272 0.05, P = 0.28), but they shared a moderate number of common variants ($nc_{12} = 131$). In addition, 273 we found that the genetic variants they share had mixed effects on the two traits (Figure 1D), 274 which explained why they had no significant genetic correlation but had strong polygenic 275 overlap.

276 The numbers of shared variants between cPUFA levels and brain disorders are limited by 277 the number of variants influencing cPUFAs. Compared with the strong polygenic overlap 278 between different brain disorders (mean $nc_{12} = 5,093$; Supplementary Figure S5 and 279 Supplementary Table S5), the average number of shared variants between cPUFAs is 76 280 (Supplementary Figure S5). We found that the number of shared variants is particularly limited 281 by the number of variants underlying each specific cPUFA. The average number of common 282 variants associated with cPUFA levels is 139, compared with 10,359 in brain disorders, a 283 difference of two orders of magnitude (Figure 1B; Supplementary Table S4). Our polygenic 284 overlap analysis revealed relatively simple genetic architecture of cPUFAs, high polygenicity of 285 brain disorders, and widespread, moderate polygenic overlap between the two groups of traits.

286

Statistical inference of causal associations between cPUFAs and brain disorders

To examine putative causal associations between six cPUFAs and 17 brain disorders, we conducted bidirectional MR analyses using GWAS summary statistics. Three brain disorders

(AD, ALZ, and OD) were not included in the MR analysis due to the absence of effect sizes andstandard errors in their GWAS summary statistics.

We identified nine pairs, for which genetically predicted cPUFAs were significantly (*P* < 0.05) associated with increased risks of brain disorders; and seven pairs, for which genetically predicted cPUFAs were associated with reduced risks of brain disorders (**Figure 2A-B and Supplementary Table S7**). Among the 16 significant pairs identified in the forward MR analysis, we did not detect any effect of brain disorders on cPUFA levels in our reverse MR analysis, except for the pair of PUFA%-MDD (**Supplementary Figure S6 and Supplementary Table S8**).

298 Among the 16 significant pairs, nine pairs presented consistent and strong evidence for 299 potential causal effects of cPUFAs on brain disorders when considering results from both genetic 300 correlation and MR (Figure 1A and 2A). Four pairs (omega-6%-CUD, PUFA%-MDD, omega-301 3%-MDD, and DHA%-MDD) showed consistent negative associations, implying potential 302 protective effects of these cPUFAs against CUD and MDD. In contrast, five pairs (PUFA%-303 AUDIT_C, omega-6%-AUDIT_C, PUFA%-AUDIT_T, omega-3%-AN, and omega-6:omega-3-304 ADHD) showed consistent positive associations, indicating that these cPUFAs might increase the 305 risks of alcohol consumption, anorexia nervosa and ADHD.

Omega-3% were genetically predicted to be associated with a reduced risk of BIP. For a one standard deviation (SD) increase in genetically predicted omega-3%, the odds ratio (OR) for BIP was 0.91 (95% CI = [0.83, 1.00]) using the IVW method (**Figure 2C and Supplementary Table S7**). Although horizontal pleiotropy was detected in the intercept test ($P_{intercept} = 0.043$), the result remained significant after correcting for possible pleiotropy with the MR-Egger approach (OR = 0.81, 95% CI = [0.70, 0.93]). The finding was consistent across other MR

methods. In the reverse MR, there was no evidence supporting a causal effect of BIP on omega-3% ($\beta_{IVW} = -0.10, 95\%$ CI = [-0.33, 0.13]) (**Supplementary Table S8**).

314 Prioritization of colocalized loci and shared variants

315 To statistically prioritize genomic loci and infer causal variants responsible for both 316 cPUFA levels and brain disorders, we conducted pairwise colocalization analysis and statistical 317 fine-mapping. This analysis revealed 44 significant colocalized regions with a PP > 0.7 (Figure 318 3A and Supplementary Table S9). The 44 significant colocalized regions correspond to 13 319 unique regions. Furthermore, 22 unique SNPs were statistically inferred as potential causal 320 variants shared between cPUFAs and brain disorders, indicating that more than one variant 321 within these colocalized regions contribute to multiple trait pairs. Among the 22 unique SNPs, 14 322 were also included in 95% CSs defined by SuSiE (Supplementary Table S9). We also 323 performed multi-trait colocalization analysis combining all cPUFAs and brain disorders. We 324 identified four candidate shared SNPs (Supplementary Table S9).

To gain insights into the functional implications of the identified colocalized SNPs, we annotated the nearest genes associated with the colocalized and fine-mapped SNPs using VEP (**Supplementary Table S10**). Additionally, we performed gene set enrichment analysis using the FUMA GENE2FUNC function [74]. This analysis revealed that the 36 prioritized genes are significantly enriched in biological pathways related to lipid metabolism (FDR adjusted P <0.05), providing further support for their potential biological relevance in the context of cPUFA levels and brain disorders (**Supplementary Table S11**).

We highlight here one example that provides insights into the role of PUFAs on brain disorders. The example involves BIP and all six cPUFA measures (**Figure 3B and 3C**), all of which share a colocalized region at the *FADS* gene cluster (chr11:58,780,549-62,223,771).

Within this region, three distinct shared SNPs (i.e., rs174564, rs174567, rs174528) were identified (**Supplementary Table S9**). To further investigate this region, we performed statistical fine-mapping analysis using SuSiE, which supported the presence of multiple causal variants for omega-3%, DHA%, PUFA% and omega-6:omega-3 (**Supplementary Figure S7**). This analysis provided additional evidence for the potential involvement of multiple causal variants within the *FADS* region in modulating the circulating levels of omega-3%, DHA%, PUFA%, and omega-6:omega-3.

342 We also performed a multi-trait colocalization analysis combining these six cPUFA 343 phenotypes with BIP. The variant rs174564 (chr11:61588305A>G) had the highest PP of 0.95 344 (Figure 3C), suggesting that it is likely the shared causal variant between cPUFAs and BIP. The 345 SNP is an intronic variant of the FADS2 gene and is known to be associated with both cPUFA 346 levels and BIP. The A allele of rs174564 was associated with an increased level of DHA% ($\beta =$ 0.28, SE = 0.004, $P < 1 \times 10^{-300}$) and omega-3% ($\beta = 0.39$, SE = 0.004, $P < 1 \times 10^{-300}$), while 347 with a reduced risk of BIP (OR = 0.93, 95% CI = [0.91, 0.95], $P = 6.24 \times 10^{-13}$). Furthermore, 348 349 MR analysis also revealed a negative association between omega-3% and BIP (Figure 2A-C). 350 Combining the results of MR and colocalization analysis, there is strong evidence supporting that 351 omega-3% has a protective effect on bipolar disorder.

352 Potential causal relationships informed by shared genetic basis

To advance our understanding of the potential causal relationship between cPUFAs and brain disorders, we compared and synthesized the findings across the multiple approaches of evaluating shared genetic basis. We designated strong evidence supporting a potential causal relationship when there are statistically significant and directionally consistent results in genetic correlation (P < 0.05), MR (P < 0.05), and colocalization (PP > 0.7). We did not include

polygenic overlap due to its ubiquity among all six cPUFA phenotypes and brain disorders. We considered that there is suggestive evidence when there were statistically significant and directionally consistent results in genetic correlation (P < 0.05) and colocalization (PP > 0.7).

361 We identified four pairs with strong evidence supporting potential causal effects of the 362 specific cPUFAs on the corresponding brain disorders (**Table 1**). For example, PUFA% is likely 363 to have protective effect on MDD with support from the following evidence: 1) PUFA% showed a negative genetic correlation with MDD ($r_g = -0.19$, $P = 7.14 \times 10^{-16}$); 2) MR results suggest 364 365 that higher PUFA% is associated with a reduced risk of MDD (OR = 0.95, 95% CI = [0.92, 0.99], 366 $P = 5.76 \times 10^{-3}$; 3) Colocalization analysis identified a colocalized region at chr21q22.3 (chr21:46,177,105-47,492,226; PP = 0.83) and a potential shared causal variant rs4818766 367 368 (chr21:46635351A>G), which is an intronic variant of gene ADARB1. SNP rs4818766 is known 369 to be associated with body fat distribution [81]. ADARB1 is highly expressed in the brain and 370 related to developmental and epileptic encephalopathy [82] and psychiatric disorders [83, 84]. In 371 addition to PUFA%, our forward MR results also show that higher levels of omega-3% and DHA% 372 were associated with a reduced risk of MDD, in line with a recent finding [23]. Interestingly, our 373 forward and reverse MR both showed negative associations between PUFA% and MDD (forward MR: OR = 0.95, 95% CI = [0.92, 0.99], $P = 5.76 \times 10^{-3}$; reverse MR: OR = 0.91, 95% 374 375 CI = [0.84, 0.99], P = 0.013), driven by different genetic variants (Supplementary Figure S8), 376 supporting a potential bidirectional relationship.

We also found that lower omega-6% are related to lower alcohol consumption (**Table 1**). Both genetic correlation ($r_g = 0.08$, P = 0.036; **Figure 4A**) and forward MR results ($\beta_{IVW} = 0.019$, P = 0.001; **Figure 4B**) revealed a positive association between omega-6% and alcohol consumption. In our colocalization analysis (**Figure 4C and 4D**), we observed that genomic

381 region 2p23.2-2p23.3 (chr2:26.894,985-28,598,777) exhibited colocalization signals among 382 three alcohol-intake phenotypes (AUDIT C, AUDIT T, AUDIT P) and five cPUFA phenotypes 383 (omega-3%, omega-6%, LA%, PUFA% and omega-6:omega-3). Within this region, SNP 384 rs1260326 (chr2:27730940T>C) was identified as a potential shared causal variant (PP = 0.99). 385 Notably, the T allele of rs1260326 was associated with lower levels of omega-6% (β = -0.11, SE = 0.004, $P = 7.0 \times 10^{-159}$), LA% (β = -0.08, SE = 0.004, $P = 1.20 \times 10^{-87}$) and lower alcohol 386 consumption (AUDIT C: $\beta = -0.007$, SE = 0.001, $P = 5.47 \times 10^{-9}$; AUDIT T: $\beta = -0.008$, SE = 387 0.001, $P = 2.11 \times 10^{-10}$; AUDIT_P: $\beta = -0.005$, SE = 0.001, $P = 6.7 \times 10^{-7}$). SNP rs1260326, a 388 389 missense variant for gene GCKR, is known to be associated with alcohol intake [85], type 2 390 diabetes [86], liver diseases [87, 88] and lipid levels such as triglyceride and cholesterol [89]. 391 Taken together evidence from genetic correlation, MR and colocalization analysis, our findings 392 indicate that lower omega-6% may lower alcohol consumption.

393 We identified eight trait pairs that display suggestive evidence for a potential causal 394 relationship. Interestingly, our genetic correlation analysis unveiled a negative correlation between ADHD and three cPUFA phenotypes: PUFA% ($r_g = -0.3$, $P = 2.51 \times 10^{-12}$), omega-6% 395 $(r_g = -0.25, P = 5.67 \times 10^{-8})$, and DHA% $(r_g = -0.32, P = 1.73 \times 10^{-10})$. Further colocalization 396 397 analysis identified a genomic locus chr9:85,440,801-86,938,196 shared among ADHD, PUFA%, 398 omega-6% and LA% (PP > 0.7; **Table 1**). Our forward MR did not reveal significant associations 399 between ADHD and the three cPUFAs. However, the reverse MR displayed significant negative associations (PUFA%: $\beta_{IVW} = -0.07$, $P = 3.48 \times 10^{-3}$; omega-6%: $\beta_{IVW} = -0.05$, P = 0.046; and 400 DHA%: $\beta_{IVW} = -0.08$, $P = 3.43 \times 10^{-3}$; Supplementary Table S8), suggesting that the presence 401 402 of ADHD might contribute to decreased circulating PUFA levels. These findings align with 403 previous research indicating that individuals with ADHD generally exhibit lower omega-3 PUFA

- 404 levels compared to the control group [14]. This ADHD example provides clues for further studies
- 405 into the intricate relationship between ADHD and cPUFAs.

406 **Discussion**

407 By leveraging GWAS summary statistics of six cPUFA phenotypes and 20 brain disorders, 408 we revealed a widespread shared genetic basis between the two groups of traits. Our MR analysis 409 found 16 pairs of cPUFAs and brain disorders that display potential causal associations. Further 410 colocalization and fine-mapping analysis led to statistically inferred candidate shared causal 411 variants, such as rs1260326 (GCKR), rs174564 (FADS2) and rs4818766 (ADARB1). We also 412 identified cPUFA-brain disorder pairs with consistent results across various analysis approaches, 413 emphasizing a prominent role of cPUFAs in brain disorders, especially MDD, BIP and alcohol 414 consumption-related phenotypes. Our discoveries provide novel insights into the intricate 415 relationships between cPUFAs and brain disorders, improving our knowledge in refining dietary 416 strategies for prevention and intervention.

417 The protective effect of PUFA% on MDD is strongly supported by various methods with 418 different model assumptions, including genetic correlation, MR and colocalization. We identified 419 a putative shared variant rs4818766 and a candidate gene ADARB1. ADARB1 encodes one of the 420 enzymes involved in the adenosine-to-inosine (A-to-I) RNA editing process known as Adenosine 421 Deaminases Acting on RNA (ADAR2) [90]. One of the leading hypotheses regarding the 422 pathogenicity of MDD is the serotonin hypothesis, which suggests that depression may arise 423 from abnormalities in neurotransmitters, particularly serotonin [90, 91]. ADAR2 could edit 424 serotonin 2C receptor (5-HT_{2c}-R) at the D site, which reduces G protein coupling and affinity for 425 serotonin [90]. Notably, prior research has shown that ADAR2 knock-out and mutant mice 426 lacking the deaminase activity of ADAR2 exhibit elevated body fat and reduced ability to utilize 427 fatty acids [92, 93]. Animal studies have also demonstrated that supplementing PUFAs in rats

leads to higher concentrations of serotonin in the brain [94]. Taken together, it is plausible thatPUFAs reduce the risk of MDD by modulating the serotonin transportation through ADAR2 [95].

430 Our study also supports the protective effect of omega-3% on BIP. MR analysis showed 431 that higher omega-3% are associated with a reduced risk of bipolar disorder. Further 432 colocalization analysis identified a colocalized region where the FADS1 and FADS2 genes are 433 located. Statistically inferred shared causal variant rs174564 is an intronic variant of the FADS2 434 gene. SNPs in the FADS1/2 region have been reported to be associated with circulating PUFA 435 levels and the risk of bipolar disorder in different populations [28, 96, 97]. Significant changes in 436 the lipid profiles of the plasma and brain, as well as behavioral changes (e.g., hyperactivity and 437 hypoactivity episodes), were observed in heterozygous Fads1/2 knockout mice [24]. Moreover, 438 dietary DHA supplementation reduced depressive episodes in the mutant mice, supporting the protective role of omega-3% against BIP. 439

440 We show that lower levels of omega-6% are related to lower alcohol consumption. We 441 statistically inferred a shared causal variant rs1260326 (gene: GCKR), which explains a 442 colocalized association signal between omega-6% levels and alcohol consumption. GCKR 443 encodes glucokinase regulatory protein that binds to glucokinase. Compared to the C allele of 444 rs1260326, the T allele results in lower binding efficiency of glucokinase regulatory protein, 445 leading to increased total fatty acids formation, liver fat and triglyceride accumulation [98]. In 446 addition, the T allele is linked to a higher risk of liver diseases, including nonalcoholic fatty liver 447 disease (NAFLD) and non-alcoholic steatohepatitis [99]. Lower serum levels of omega-6 fatty 448 acids and LA were associated with a higher risk for NAFLD [100]. Taken together, it is possible 449 that individuals with lower PUFA and omega-6 levels tend to have more liver problems (e.g.,

450 accumulation of liver fat, elevated levels of triglyceride, and alanine aminotransferase), and thus451 tend to drink less.

452 We note that disease status itself might influence cPUFA levels. Our reverse MR results 453 revealed a significant negative association between ADHD and three cPUFAs (PUFA%, omega-6% 454 and LA%), suggesting that altered cPUFA levels may be one of the metabolic consequences of 455 ADHD. Further pairwise colocalization analysis identified a region chr9:85,440,801-86,938,196 456 colocalized among ADHD, PUFA%, omega-6% and LA% (Table 1 and Supplementary Table 457 **S9**). Three distinct SNPs (i.e., rs2576362, rs1982151, rs6559744) were statistically inferred as 458 putative causal variants that explain the shared association signal. However, none of the 459 identified SNP has strong enough evidence for causation (PP < 0.1), and further studies are 460 needed to pinpoint shared causal variants and candidate genes in this region.

461 The discrepancy between the genetic correlation and MR results could be attributed to the 462 differences in the sets of genetic variants analyzed in either approach and the existence of 463 discordant pleiotropy across variants. It also reflects the limitations of different methods as well 464 as the complex genetic architecture of brain disorders [101]. Taking omega-3% and BIP as an 465 example, their positive genetic correlation suggests the presence of a substantial number of 466 common variants that exert small yet consistent effects on both phenotypes (Supplementary 467 Figure S9). However, the negative association observed in MR and colocalization analysis is 468 driven by the FADS locus that exhibited a relatively large effect but with opposite directions on 469 the two phenotypes (Supplementary Figure S8 and Supplementary Table S12). We highlight 470 the need to understand the biological function of genetic variants in MR analysis, especially 471 when the trait of interest has complicated genetic architecture [101, 102].

472 In our analysis, we focused on relative measures of cPUFAs. We found limited genetic 473 correlations or polygenic overlaps between the absolute measures of cPUFAs and brain disorders 474 (Supplementary Figure S3-S4 and Table S3-S4). It is important to note that absolute and 475 relative measures of cPUFAs offer distinct perspectives on fatty acid metabolism. Relative 476 measures are preferred in the majority of cases because PUFAs as well as saturated and 477 monounsaturated fatty acids are metabolized by the same enzymes derived from common genes 478 (e.g. FADS1/FADS2) [103]. They are also preferred because relative measures are more precise 479 (lower analytical SDs) since they are all referenced to one another and not to exogenously-added 480 internal standards. Absolute measures provide direct information about the quantities of cPUFAs 481 which become important when any particular fatty acid may become limiting for a particular 482 physiological requirement [104-106]. The different patterns with brain disorders are consistent 483 with the limited genetic correlation between absolute and relative cPUFAs (Supplementary 484 Figure S2). They likely reflect different aspects of lipid metabolism. Future studies are needed to 485 discern the exact mechanisms.

486 Our study is not without limitations. First, using different GWAS summary statistics 487 could lead to minor differences in the results since slightly different analytical strategies were 488 applied (e.g., association methods, quality control criteria, and covariates). To address this issue, 489 we analyzed multiple GWAS of the same phenotype to evaluate robustness of our discoveries. 490 We observed consistent correlation patterns with different GWAS of the same traits 491 (Supplementary Figure S3 and Supplementary Table S3). Second, five brain disorders (i.e., 492 ANX, OCD, OD, AD, and TS) had relatively small sample sizes that did not meet the 493 requirement of MiXeR and were therefore excluded from the estimation of polygenic overlap. 494 Finally, our study focused only on the European population. Genetic adaptation and variation of

fatty acid composition have been demonstrated in the Inuit, African, South Asian, East Asian, and European populations [23, 107-109]. Differences in prevalence [110, 111] and genetic risk factors [89] of psychiatric disorders were also demonstrated across ethnic groups. Therefore, expanding our research to other populations is necessary to gain a deeper understanding of the shared genetic basis and genetic determinants between cPUFAs and brain disorders across populations.

501 Our systemic genetic analysis of six cPUFA traits and 20 brain disorders uncovered a 502 widespread shared genetic basis between the two groups. We pinpointed specific shared genetic 503 variants and provided evidence supporting the potential effects of certain cPUFAs on specific 504 brain disorders. Our findings provide new insights into the shared genetic architecture underlying 505 these traits and have implications for interventions and dietary recommendations of PUFAs in the 506 context of brain disorders.

507 Supplemental information description

- 508 Figure S1. Flowchart of the study
- 509 Figure S2. Pairwise genetic correlations A) between brain disorders and B) between cPUFA
- 510 phenotypes.
- 511 Figure S3. Pairwise genetic correlations between cPUFAs and brain disorders
- 512 Figure S4. Pairwise polygenic overlaps between cPUFAs and brain disorders
- 513 Figure S5. Pairwise polygenic overlaps A) between brain disorders and B) between cPUFAs.
- 514 Figure S6. Reverse MR results
- 515 Figure S7. Statistical fine-mapping posterior inclusion probability plots in 11q12.1-11q12.3 for A)
- 516 omega-3%, B) DHA%, C) PUFA% and D) omega-6:omega-3
- 517 Figure S8. Bidirectional association between PUFA% and MDD
- 518 Figure S9. Differences in the SNP sets in omega-3%-BIP genetic correlation and MR analysis
- 519 Table S1. Literature review on PUFA-brain disorders Mendelian randomization studies
- 520 Table S2. Dataset characteristics
- 521 Table S3. Pairwise genetic correlations between cPUFAs and brain disorders
- 522 Table S4. MiXeR univariate estimates and bivariate estimates between cPUFAs and brain
- 523 disorders
- 524 Table S5. MiXeR bivariate estimates between brain disorders
- 525 Table S6. MiXeR bivariate estimates between cPUFAs
- 526 Table S7. Forward MR results inferring the causal effect of cPUFAs on brain disorders
- 527 Table S8. Reverse MR results inferring the causal effect of brain disorders on cPUFAs levels
- 528 Table S9. Pairwise colocalization analysis and fine-mapping results
- 529 Table S10. Functional annotation of colocalized and fine-mapped SNPs by VEP
- Table S11. Gene-set enrichment analysis of 36 candidate genes using FUMA GENE2FUNC
- Table S12. Genetic instruments included in the omega-3%-BIP MR analysis

532 Abbreviations

1KGP	1000 Genomes Project
AD	Alcohol dependence
ADARB1	Adenosine Deaminase RNA Specific B1
ADHD	Attention deficit-hyperactivity disorder
ALZ	Alzheimer's disease
AN	Anorexia nervosa
ANX	Anxiety disorders and factors
ASD	Autism spectrum disorder
AUDIT	Alcohol use disorder identification test
AUDIT_C	AUDIT focusing on alcohol consumption
AUDIT_P	AUDIT focusing on the problematic consequences of drinking
AUDIT_T	AUDIT total score
BIP	Bipolar disorder
cPUFA	Circulating polyunsaturated fatty acids
CS	Credible set
CUD	Cannabis use disorder
DHA	Docosahexaenoic acid
FADS	Fatty acid desaturase
GCKR	Glucokinase regulatory protein
GWAS	Genome-wide association study
h^2	Heritability
INS	Insomnia
IVW	Inverse weighted variance
LA	Linoleic acid
LD	Linkage disequilibrium
LDSC	LD Score regression
MAF	Minor allele frequency
MDD	Major depression
MHC	Major histocompatibility complex
MOOD	Mood disorders
MR	Mendelian randomization
NAFLD	Nonalcoholic fatty liver disease
nc12	Number of common variants shared between trait1 and trait2
NE	Neuroticism
OCD	Obsessive-compulsive disorder
OD	Opioid dependence
PGC	Psychiatric Genomic Consortium
PP	Posterior probability
PTSD	Post-traumatic stress disorder
PUFA	Polyunsaturated fatty acids
r _g	Genetic correlation coefficient

SCZ	Schizophrenia
SNP	Single-nucleotide polymorphism
TS	Tourette syndrome
VEP	Variant Effect Predictor

534 Acknowledgements

Research reported in this publication was supported by the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number R35GM143060. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We thank the PGC, IEU Open GWAS, and CNCR for providing access to genome-wide association study data. We also thank all research participants who provided DNA samples for these studies. We thank the UGA GACRC staff for facilitating our data analysis.

542

543 **Conflict of Interest**

544 The authors report no conflicts of interest.

545

546 Author contributions

547 K.Y. conceptualized and supervised the study. K.Y., H.X., and Y.S. designed the analysis.

548 H.X. collected data. H.X. and Y.S. performed most data analysis with assistance from M.F.,

549 N.T.R.M., and C.F.C.. H.X., Y.S., K.Y., J.T.B., and C.W.K.C. interpreted the results and wrote the

550 manuscript. All authors reviewed, revised, and approved the manuscript.

551 **References**

- 5521.Diseases, G.B.D. and C. Injuries, Global burden of 369 diseases and injuries in 204553countries and territories, 1990-2019: a systematic analysis for the Global Burden of554Disease Study 2019. Lancet, 2020. **396**(10258): p. 1204-1222.
- 555 2. Collaborators, G.B.D.M.D., *Global, regional, and national burden of 12 mental disorders*556 *in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden*557 *of Disease Study 2019.* Lancet Psychiatry, 2022. 9(2): p. 137-150.
- Bradvik, L., *Suicide Risk and Mental Disorders*. Int J Environ Res Public Health, 2018.
 15(9).
- 5604.Sarris, J., et al., Nutritional medicine as mainstream in psychiatry. The Lancet Psychiatry,5612015. 2(3): p. 271-274.
- 5. Firth, J., et al., *The efficacy and safety of nutrient supplements in the treatment of*563 *mental disorders: a meta-review of meta-analyses of randomized controlled trials.* World
 564 Psychiatry, 2019. **18**(3): p. 308-324.
- 565 6. Bazinet, R.P. and S. Layé, *Polyunsaturated fatty acids and their metabolites in brain* 566 *function and disease.* Nature Reviews Neuroscience, 2014. **15**(12): p. 771-785.
- 567 7. Brenna, J.T., Animal studies of the functional consequences of suboptimal
 568 polyunsaturated fatty acid status during pregnancy, lactation and early post-natal life.
 569 Matern Child Nutr, 2011. 7 Suppl 2(Suppl 2): p. 59-79.
- 5708.Melo, H.M., L.E. Santos, and S.T. Ferreira, Diet-Derived Fatty Acids, Brain Inflammation,571and Mental Health. Front Neurosci, 2019. 13: p. 265.
- 572 9. Lin, P.Y., S.Y. Huang, and K.P. Su, *A meta-analytic review of polyunsaturated fatty acid* 573 *compositions in patients with depression.* Biol Psychiatry, 2010. **68**(2): p. 140-7.
- 57410.Liao, Y., et al., Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl575Psychiatry, 2019. **9**(1): p. 190.
- 57611.Thesing, C.S., et al., Omega-3 and omega-6 fatty acid levels in depressive and anxiety577disorders. Psychoneuroendocrinology, 2018. 87: p. 53-62.
- Amminger, G.P., et al., Long-chain omega-3 fatty acids for indicated prevention of *psychotic disorders: a randomized, placebo-controlled trial.* Arch Gen Psychiatry, 2010.
 67(2): p. 146-54.
- 58113.Amminger, G.P., et al., Longer-term outcome in the prevention of psychotic disorders by582the Vienna omega-3 study. Nat Commun, 2015. 6: p. 7934.
- 583 14. Chang, J.P., et al., Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit
 584 Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and
 585 Biological Studies. Neuropsychopharmacology, 2018. 43(3): p. 534-545.
- 586 15. Mazahery, H., et al., *Relationship between long chain n-3 polyunsaturated fatty acids* 587 *and autism spectrum disorder: systematic review and meta-analysis of case-control and* 588 *randomised controlled trials*. Nutrients, 2017. **9**(2): p. 155.
- 58916.Cederholm, T., N. Salem Jr, and J. Palmblad, ω -3 fatty acids in the prevention of cognitive590decline in humans. Advances in nutrition, 2013. 4(6): p. 672-676.
- 59117.Deane, K.H.O., et al., Omega-3 and polyunsaturated fat for prevention of depression and592anxiety symptoms: systematic review and meta-analysis of randomised trials. Br J
- 593 Psychiatry, 2021. **218**(3): p. 135-142.

594 Mazereeuw, G., et al., Effects of omega-3 fatty acids on cognitive performance: a meta-18. 595 analysis. Neurobiol Aging, 2012. 33(7): p. 1482 e17-29. 596 19. McGorry, P.D., et al., Effect of ω -3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA 597 598 psychiatry, 2017. **74**(1): p. 19-27. 599 Cheng, N., et al., Effects of omega-3 polyunsaturated fatty acid supplementation on 20. 600 cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial. BJPsych open, 2022. 8(5): p. e165. 601 602 21. loannidis, J.P.A., The Challenge of Reforming Nutritional Epidemiologic Research. JAMA, 603 2018. **320**(10): p. 969-970. 604 van Rheenen, W., et al., Genetic correlations of polygenic disease traits: from theory to 22. 605 practice. Nat Rev Genet, 2019. 20(10): p. 567-581. 606 23. Davyson, E., et al., Metabolomic Investigation of Major Depressive Disorder Identifies a 607 Potentially Causal Association With Polyunsaturated Fatty Acids. Biol Psychiatry, 2023. 608 24. Yamamoto, H., et al., GWAS-identified bipolar disorder risk allele in the FADS1/2 gene 609 region links mood episodes and unsaturated fatty acid metabolism in mutant mice. Mol 610 Psychiatry, 2023. 611 Milaneschi, Y., et al., A role for vitamin D and omega-3 fatty acids in major depression? 25. 612 An exploration using genomics. Transl Psychiatry, 2019. 9(1): p. 219. 613 26. Jones, H.J., et al., Associations between plasma fatty acid concentrations and 614 schizophrenia: a two-sample Mendelian randomisation study. The Lancet Psychiatry, 615 2021. **8**(12): p. 1062-1070. 616 27. Gao, Y., et al., Association between Arachidonic Acid and the Risk of Schizophrenia: A 617 Cross-National Study and Mendelian Randomization Analysis. Nutrients, 2023. 15(5): p. 618 1195. 619 Zhao, L., et al., Replicated associations of FADS1, MAD1L1, and a rare variant at 10q26. 28. 620 13 with bipolar disorder in Chinese population. Translational Psychiatry, 2018. 8(1): p. 621 270. 622 Schizophrenia Working Group of the Psychiatric Genomics, C., *Biological insights from* 29. 108 schizophrenia-associated genetic loci. Nature, 2014. 511(7510): p. 421-7. 623 624 30. Howard, D.M., et al., Genome-wide meta-analysis of depression identifies 102 625 independent variants and highlights the importance of the prefrontal brain regions. Nat 626 Neurosci, 2019. 22(3): p. 343-352. 627 Mullins, N., et al., Genome-wide association study of more than 40,000 bipolar disorder 31. 628 cases provides new insights into the underlying biology. Nature genetics, 2021. 53(6): p. 629 817-829. 630 32. International Obsessive Compulsive Disorder Foundation Genetics, C. and O.C.D.C.G.A. 631 Studies, Revealing the complex genetic architecture of obsessive-compulsive disorder 632 using meta-analysis. Mol Psychiatry, 2018. 23(5): p. 1181-1188. 633 Otowa, T., et al., Meta-analysis of genome-wide association studies of anxiety disorders. 33. 634 Mol Psychiatry, 2016. 21(10): p. 1485. 635 Nievergelt, C.M., et al., International meta-analysis of PTSD genome-wide association 34. 636 studies identifies sex- and ancestry-specific genetic risk loci. Nat Commun, 2019. 10(1): p. 637 4558.

638 639	35.	Watson, H.J., et al., <i>Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa.</i> Nat Genet, 2019. 51 (8): p.
640		1207-1214.
641	36.	Grove, J., et al., Identification of common genetic risk variants for autism spectrum
642		<i>disorder.</i> Nat Genet, 2019. 51 (3): p. 431-444.
643 644	37.	Yu, D., et al., Interrogating the genetic determinants of Tourette's syndrome and other tic disorders through genome-wide association studies. American Journal of Psychiatry.
645		2019. 176 (3): p. 217-227.
646	38.	Demontis. D., et al., Discovery of the first genome-wide significant risk loci for attention
647		deficit/hyperactivity disorder. Nat Genet. 2019. 51 (1): p. 63-75.
648	39.	Watanabe, K., et al., Genome-wide meta-analysis of insomnia prioritizes genes
649		associated with metabolic and psychiatric pathways. Nat Genet, 2022. 54(8): p. 1125-
650		1132.
651	40.	Werme, J., et al., Genome-wide gene-environment interactions in neuroticism: an
652		exploratory study across 25 environments. Transl Psychiatry, 2021. 11(1): p. 180.
653	41.	Wightman, D.P., et al., A genome-wide association study with 1,126,563 individuals
654		identifies new risk loci for Alzheimer's disease. Nat Genet, 2021. 53(9): p. 1276-1282.
655	42.	Polimanti, R., et al., Leveraging genome-wide data to investigate differences between
656		opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics
657		Consortium. Molecular psychiatry, 2020. 25 (8): p. 1673-1687.
658	43.	Johnson, E.C., et al., A large-scale genome-wide association study meta-analysis of
659		cannabis use disorder. Lancet Psychiatry, 2020. 7(12): p. 1032-1045.
660	44.	Walters, R.K., et al., Transancestral GWAS of alcohol dependence reveals common
661		genetic underpinnings with psychiatric disorders. Nat Neurosci, 2018. 21(12): p. 1656-
662		1669.
663	45.	Sanchez-Roige, S., et al., Genome-Wide Association Study Meta-Analysis of the Alcohol
664		Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. Am J
665		Psychiatry, 2019. 176 (2): p. 107-118.
666	46.	Lyon, M.S., et al., The variant call format provides efficient and robust storage of GWAS
667		summary statistics. Genome Biol, 2021. 22 (1): p. 32.
668	47.	Sullivan, P.F., et al., <i>Psychiatric Genomics: An Update and an Agenda</i> . Am J Psychiatry,
669		2018. 175 (1): p. 15-27.
670	48.	Pardinas, A.F., et al., Common schizophrenia alleles are enriched in mutation-intolerant
671		genes and in regions under strong background selection. Nat Genet, 2018. 50 (3): p. 381-
672		389.
673	49.	Duncan, L.E., et al., Largest GWAS of PTSD (N=20 070) yields genetic overlap with
674		schizophrenia and sex differences in heritability. Mol Psychiatry, 2018. 23(3): p. 666-673.
675	50.	Forstner, A.J., et al., Genome-wide association study of panic disorder reveals genetic
6/6	- 4	overlap with neuroticism and depression. Mol Psychiatry, 2021. 26(8): p. 41/9-4190.
6/7	51.	Neale, B.M., et al., Meta-analysis of genome-wide association studies of attention-
6/8	50	<i>aejicit/nyperactivity disorder.</i> J Am Acad Child Adolesc Psychiatry, 2010. 49 (9): p. 884-97.
6/9	52.	Hinrichs, A.S., et al., The UCSC Genome Browser Database: update 2006. Nucleic Acids
680		Res, 2006. 34 (Database issue): p. D590-8.

681 682	53.	Murphy, A.E., B.M. Schilder, and N.G. Skene, <i>MungeSumstats: A Bioconductor package</i> for the standardisation and auglity control of many GWAS summary statistics.
683		Bioinformatics 2021. $37(23)$: p. 4593-6.
684	54.	Bulik-Sullivan, B.K., et al., I.D. Score regression distinguishes confounding from
685	0.11	polygenicity in genome-wide association studies. Nat Genet 2015 47 (3): p. 291-5
686	55	Bulik-Sullivan B et al An atlas of genetic correlations across human diseases and traits
687	55.	Nat Genet, 2015. 47 (11): p. 1236-41.
688 689	56.	Genomes Project, C., et al., A global reference for human genetic variation. Nature, 2015. 526 (7571): p. 68-74.
690	57.	Wei, T., et al., package 'corrplot': visualization of a correlation matrix (Version 0.92).
691		2021. 2022.
692	58.	Holland, D., et al., Beyond SNP heritability: Polygenicity and discoverability of phenotypes
693		estimated with a univariate Gaussian mixture model. PLoS Genetics, 2020. 16 (5): p.
694		e1008612.
695	59.	Frei, O., et al., Bivariate causal mixture model quantifies polygenic overlap between
696		complex traits beyond genetic correlation. Nature communications, 2019. 10(1): p. 2417.
697	60.	Gu, Z., R. Eils, and M. Schlesner, Complex heatmaps reveal patterns and correlations in
698		multidimensional genomic data. Bioinformatics, 2016. 32 (18): p. 2847-9.
699	61.	Davey Smith, G. and S. Ebrahim, 'Mendelian randomization': can genetic epidemiology
700		contribute to understanding environmental determinants of disease? International
701		journal of epidemiology, 2003. 32 (1): p. 1-22.
702	62.	Burgess, S., A. Butterworth, and S.G. Thompson, Mendelian randomization analysis with
703		<i>multiple genetic variants using summarized data.</i> Genet Epidemiol, 2013. 37 (7): p. 658-
704		65.
705	63.	Bowden, J., G. Davey Smith, and S. Burgess, Mendelian randomization with invalid
706		instruments: effect estimation and bias detection through Egger regression. International
707		journal of epidemiology, 2015. 44 (2): p. 512-525.
708	64.	Bowden, J., et al., Consistent estimation in Mendelian randomization with some invalid
709		<i>instruments using a weighted median estimator</i> . Genetic epidemiology, 2016. 40 (4): p.
710		304-314.
711	65.	Hartwig, F.P., G. Davey Smith, and J. Bowden, <i>Robust inference in summary data</i>
712		Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol,
713		2017. 46 (6): p. 1985-1998.
714	66.	Verbanck, M., et al., Detection of widespread horizontal pleiotropy in causal relationships
715		inferred from Mendelian randomization between complex traits and diseases. Nature
716		genetics, 2018. 50 (5): p. 693-698.
717	67.	Greco, M.F., et al., Detecting pleiotropy in Mendelian randomisation studies with
718		summary data and a continuous outcome. Stat Med, 2015. 34 (21): p. 2926-40.
719	68.	Bowden, J., et al., Improving the visualization, interpretation and analysis of two-sample
720		summary data Mendelian randomization via the Radial plot and Radial regression. Int J
721		Epidemiol, 2018. 47 (4): p. 1264-1278.
722	69.	Korthauer, K., et al., A practical guide to methods controlling false discoveries in
723		<i>computational biology</i> . Genome Biol, 2019. 20 (1): p. 118.

724 725	70.	Hemani, G., et al., The MR-Base platform supports systematic causal inference across the human phenome Elife 2018 7
726	71	Foley C N et al. A fast and efficient colocalization algorithm for identifying shared
720	, די	aenetic risk factors across multiple traits Nat Commun 2021 12 (1): n 764
728	72	Weissbrod O et al Eurotionally informed fine-manning and polygenic localization of
729	, 2.	complex trait heritability Nat Genet 2020 52 (12): n 1355-1363
730	73	McLaren W et al The Ensembl Variant Effect Predictor Genome Biol 2016 17 (1): n
731	/ 51	
732	74	Watanabe K et al Eunctional manning and annotation of genetic associations with
733	,	FUMA. Nat Commun 2017, 8 (1): p. 1826.
734	75.	Consortium, G.T., Human genomics, The Genotype-Tissue Expression (GTEx) pilot analysis:
735	/01	multitissue gene regulation in humans Science 2015 348 (6235); p. 648-60
736	76	Francis M et al Eifty-one novel and renlicated GWAS loci for polyunsaturated and
737	, 01	monounsaturated fatty acids in 124 024 Europeans medRxiv 2022 n 2022 05
738		27.22275343.
739	77.	Brainstorm, C., et al., Analysis of shared heritability in common disorders of the brain.
740		Science, 2018, 360 (6395).
741	78.	Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address.
742		p.m.h.e. and C. Cross-Disorder Group of the Psychiatric Genomics, <i>Genomic</i>
743		Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders.
744		Cell, 2019. 179 (7): p. 1469-1482 e11.
745	79.	Grotzinger, A.D., et al., Genetic architecture of 11 major psychiatric disorders at
746		biobehavioral, functional genomic and molecular genetic levels of analysis. Nature
747		genetics, 2022. 54 (5): p. 548-559.
748	80.	Romero, C., et al., Exploring the genetic overlap between twelve psychiatric disorders.
749		Nature genetics, 2022: p. 1-8.
750	81.	Pulit, S.L., et al., Meta-analysis of genome-wide association studies for body fat
751		distribution in 694 649 individuals of European ancestry. Hum Mol Genet, 2019. 28 (1): p.
752		166-174.
753	82.	Maroofian, R., et al., Biallelic variants in ADARB1, encoding a dsRNA-specific adenosine
754		deaminase, cause a severe developmental and epileptic encephalopathy. J Med Genet,
755		2021. 58 (7): p. 495-504.
756	83.	Kubota-Sakashita, M., et al., A role of ADAR2 and RNA editing of glutamate receptors in
757		mood disorders and schizophrenia. Molecular brain, 2014. 7(1): p. 1-14.
758	84.	Karanovic, J., et al., Joint effect of ADARB1 gene, HTR2C gene and stressful life events on
759		suicide attempt risk in patients with major psychiatric disorders. World J Biol Psychiatry,
760		2015. 16 (4): p. 261-71.
761	85.	Clarke, T.K., et al., Genome-wide association study of alcohol consumption and genetic
762		overlap with other health-related traits in UK Biobank (N=112 117). Mol Psychiatry, 2017.
763		22 (10): p. 1376-1384.
764	86.	Mahajan, A., et al., Fine-mapping type 2 diabetes loci to single-variant resolution using
765		high-density imputation and islet-specific epigenome maps. Nat Genet, 2018. 50 (11): p.
766		1505-1513.

767	87.	Anstee, Q.M., et al., Genome-wide association study of non-alcoholic fatty liver and
768		steatohepatitis in a histologically characterised cohort(🖈). J Hepatol, 2020. 73 (3): p.
769		505-515.
770	88.	Santoro, N., et al., Variant in the glucokinase regulatory protein (GCKR) gene is
771		associated with fatty liver in obese children and adolescents. Hepatology, 2012. 55(3): p.
772		781-789.
773	89.	Willer, C.J., et al., Discovery and refinement of loci associated with lipid levels. Nat Genet,
774		2013. 45 (11): p. 1274-1283.
775	90.	Barbon, A. and C. Magri, RNA Editing and Modifications in Mood Disorders. Genes
776		(Basel), 2020. 11 (8).
777	91.	Albert, P.R., C. Benkelfat, and L. Descarries, The neurobiology of depression—revisiting
778		the serotonin hypothesis. I. Cellular and molecular mechanisms. 2012, The Royal Society.
779		p. 2378-2381.
780	92.	Singh, M., et al., Hyperphagia-mediated obesity in transgenic mice misexpressing the
781		RNA-editing enzyme ADAR2. Journal of Biological Chemistry, 2007. 282(31): p. 22448-
782		22459.
783	93.	Horsch, M., et al., Requirement of the RNA-editing enzyme ADAR2 for normal physiology
784		<i>in mice.</i> J Biol Chem, 2011. 286 (21): p. 18614-22.
785	94.	Levant, B., N-3 (omega-3) polyunsaturated Fatty acids in the pathophysiology and
786		treatment of depression: pre-clinical evidence. CNS Neurol Disord Drug Targets, 2013.
787		12 (4): p. 450-9.
788	95.	Gopaldas, M., et al., Brain serotonin transporter binding, plasma arachidonic acid and
789		depression severity: A positron emission tomography study of major depression. J Affect
790		Disord, 2019. 257 : p. 495-503.
791	96.	Burghardt, K.J., et al., Fatty Acid desaturase gene polymorphisms and metabolic
792		measures in schizophrenia and bipolar patients taking antipsychotics. Cardiovasc
793		Psychiatry Neurol, 2013. 2013 : p. 596945.
794	97.	Koga, N., et al., Altered polyunsaturated fatty acid levels in relation to proinflammatory
795		cytokines, fatty acid desaturase genotype, and diet in bipolar disorder. Transl Psychiatry,
796		2019. 9 (1): p. 208.
797	98.	Brouwers, M., et al., Modulation of Glucokinase Regulatory Protein: A Double-Edged
798		<i>Sword?</i> Trends Mol Med, 2015. 21 (10): p. 583-594.
799	99.	Tan, H.L., et al., Association of glucokinase regulatory gene polymorphisms with risk and
800		severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J
801		Gastroenterol, 2014. 49 (6): p. 1056-64.
802	100.	Makela, T.N.K., et al., Associations of serum n-3 and n-6 polyunsaturated fatty acids with
803		prevalence and incidence of nonalcoholic fatty liver disease. Am J Clin Nutr, 2022. 116 (3):
804		р. 759-770.
805	101.	Wootton, R.E., H.J. Jones, and H.M. Sallis, Mendelian randomisation for psychiatry: how
806		does it work, and what can it tell us? Molecular psychiatry, 2022. 27(1): p. 53-57.
807	102.	Bjornson, E., et al., Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and
808		risk of coronary heart disease: a UK Biobank study. Eur Heart J, 2023.

809	103.	Brenna, J.T. and K.S.D. Kothapalli, New understandings of the pathway of long-chain
810		polyunsaturated fatty acid biosynthesis. Curr Opin Clin Nutr Metab Care, 2022. 25(2): p.
811		60-66.
812	104.	Mocking, R.J., et al., Statistical methodological issues in handling of fatty acid data:
813		percentage or concentration, imputation and indices. Lipids, 2012. 47(5): p. 541-7.
814	105.	Sergeant, S., et al., Impact of methods used to express levels of circulating fatty acids on
815		the degree and direction of associations with blood lipids in humans. Br J Nutr, 2016.
816		115 (2): p. 251-61.
817	106.	Brenna, J.T., et al., Best practices for the design, laboratory analysis, and reporting of
818		<i>trials involving fatty acids</i> . Am J Clin Nutr, 2018. 108 (2): p. 211-227.
819	107.	Kothapalli, K.S., et al., Positive Selection on a Regulatory Insertion-Deletion
820		Polymorphism in FADS2 Influences Apparent Endogenous Synthesis of Arachidonic Acid.
821		Mol Biol Evol, 2016. 33 (7): p. 1726-39.
822	108.	Ye, K., et al., Dietary adaptation of FADS genes in Europe varied across time and
823		geography. Nat Ecol Evol, 2017. 1 : p. 167.
824	109.	Chiang, C.W.K., et al., A Comprehensive Map of Genetic Variation in the World's Largest
825		Ethnic Group-Han Chinese. Mol Biol Evol, 2018. 35 (11): p. 2736-2750.
826	110.	Harris, K.M., M.J. Edlund, and S. Larson, Racial and ethnic differences in the mental
827		health problems and use of mental health care. Med Care, 2005. 43 (8): p. 775-84.
828	111.	Breslau, J., et al., Lifetime risk and persistence of psychiatric disorders across ethnic
829		groups in the United States. Psychol Med, 2005. 35 (3): p. 317-27.
830		

		Genetic correlation		MR		Colocalization								,	
Triat1	Trait2	r _g	Р	β_{IVW}	P _{IVW}	colocalized regions	РР	Candidate SNP	A1	A2	β1 (SE1)	β2 (SE2)	<i>P1</i>	P2	
Strong evider	nce														
PUFA%	MDD	-0.193	7.14E-16	-0.051	0.006	chr21q22.3	0.829	rs4818766	G	А	-0.019 (0.004)	0.022 (0.005)	1.30E-06	6.38E-07	
PUFA%	AUDIT_C	0.116	2.0E-3	0.014	0.019	chr2p23.2	0.996	rs1260326	С	Т	0.090 (0.004)	0.007 (0.001)	9.8E-113	5.47E-09	
Omega-6%	AUDIT_C	0.084	0.036	0.019	0.001	chr2p23.2	0.996	rs1260326	С	Т	0.109 (0.004)	0.007 (0.001)	7.0E-159	5.47E-09	
PUFA%	AUDIT_T	0.079	0.037	0.014	0.049	chr2p23.2	0.999	rs1260326	С	Т	0.090 (0.004)	0.008 (0.001)	9.8E-113	2.11E-10 g	
Suggestive ev	vidence													de av	
LA%	ADHD	-0.338	3.25E-13	-0.070	0.230	chr9q21.32	0.768	rs2576362	Т	G	0.025 (0.005)	-0.067 (0.015)	8.20E-08	1.30E-05	
PUFA%	ADHD ^a	-0.301	2.51E-12	-0.089	0.151	chr9q21.32	0.722	rs6559744	А	G	0.025 (0.005)	-0.067 (0.015)	1.90E-08	1.26E-05 der	
DHA%	AN	0.276	6.35E-12	0.072	0.248	chr6q16.1	0.797	rs1487445	Т	С	0.020 (0.004)	0.056 (0.013)	4.30E-07	2.70E-05	
Omega-6%	ADHD ^a	-0.254	5.67E-08	-0.062	0.306	chr9q21.32	0.755	rs1982151	G	А	-0.026 (0.005)	0.068 (0.015)	1.70E-08	1.04E-05	
DITEV %	SC7	0.100	2 OF 4	0.062	0 364-	chr12q24.31	0.858	rs2851447	С	G	-0.022 (0.005)	-0.091 (0.012)	1.70E-06	2.19E-14	
1017/0	JCL		0.100	2.01-4	0.002	0.304	chr1p36.11	0.854	rs79598313	Т	С	-0.081 (0.013)	-0.141 (0.035)	3.00E-09	4.86E-05
Omega-3%	SCZ	0.091	0.006	0.013	0.815	chr6p21.33	0.818	rs2596500	С	А	-0.027 (0.006)	-0.166 (0.018)	1.10E-06	1.16E-19	
Omega-6%	SCZ	0.077	0.006	0.015	0.779	chr12q24.31	0.702	rs2851447	С	G	-0.024 (0.005)	-0.091 (0.012)	2.30E-07	2.19E-14	
Omega-6:	DID	0.068	0.042	0.041	0.420-	chr6p22.1	0.790	rs3094067	G	Т	0.029 (0.006)	-0.103 (0.016)	7.20E-06	9.88E-11	
Omega-3	DIF	DIF	-0.008	0.042	0.041	0.429	chr6p21.33	0.877	rs3130490	Т	G	0.028 (0.006)	-0.082 (0.016)	3.30E-06	1.30E-07

Table 1. Evidence supporting the potential role of cPUFAs in brain disorders

1

2 Note: rg, genetic correlation; β_{IVW} , estimated effects of trait 1 on trait 2 using IVW method; PP, posterior probability. A1, effect allele; A2, reference allele. β_{1} , SE1 and β_{2} , SE2 are 3 genetic effects and standard errors of A1 on trait 1 and trait 2, respectively. P1 and P2 are P values for trait 1 and trait 2 extracted from GWAS summary statistics, respectively. 4 ^aThe MR of the PUFA-ADHD significant $(P_{\rm IVW})$ pairs results 0.05). reverse two showed <

835 Figures





837 Figure 1: Widespread, moderate genetic basis shared between cPUFAs and brain disorders. A) Pairwise genetic correlations between six cPUFAs and 20 brain disorders. P-value cutoffs of 838 0.05, 0.001, 4.17×10^{-4} are used to represent increasing levels of statistical significance; colors are 839 840 used to represent degree of genetic correlation (r_{o}) between two traits. **B**) Pairwise polygenic 841 overlaps between six cPUFAs and 15 brain disorders. The color and number of each box indicate 842 the degree of polygenic overlap and number of causally associated SNPs shared between 843 cPUFAs and brain disorders (nc_{12}) . Bar plots on the top and left indicate the number of cPUFAs-844 and brain disorders- associated variants, respectively, which explain 90% of SNP-based 845 heritability. Two cPUFA-brain disorder pairs highlighted in the red boxes correspond to panels C) 846 and D). C) Genetic effects of genome-wide SNPs on PUFA% (x axis) and NE (y axis). D) 847 Genetic effects of genome-wide SNPs on LA% (x axis) and AUDIT_C (y axis). Each dot 848 represents a genetic variant; colors indicate variant density.



849

850 Figure 2. Statistical inference of causal relationship between cPUFAs and brain disorders. A) A heatmap summarizing the effects of six cPUFAs on 17 brain disorders. IVW p-value of 0.05 851 852 is used to represent statistical significance. Colors represent the effects (β_{IVW}) of cPUFAs on 853 brain disorders. The pair of omega-3% and BIP highlighted in the red box corresponds to panel C). B) MR results showing a significant association between cPUFAs and brain disorders. Beta 854 855 and OR estimated using IVW method are used to represent the effects of cPUFAs on continuous 856 and binary outcomes, respectively. C) MR estimated effects of omega-3% (x axis) on BIP (y 857 axis). Effects estimated by the four models are shown by fitted lines; slopes of these lines 858 indicate the effect sizes.



859

Figure 3. Colocalization analysis detects genomic loci shared between cPUFAs and brain 860 861 disorders. A) A heatmap summarizing pairwise colocalization between six cPUFAs and 17 brain 862 disorders. The color and number of each box indicate the number of significant colocalized regions between cPUFAs and brain disorders (PP > 0.7). Bar plots on the top and left indicate the 863 numbers of unique colocalized SNPs (black) and loci (grey, PP > 0.7) for cPUFAs and brain 864 865 disorders, respectively. B) Regional association plots of six cPUFA phenotypes and BIP in 866 chr11:61,520,000-61,660,000. Variant positions are shown on x axis, $-\log_{10}P$ on the left y axis, recombination rate on the right y axis; variant rs174564 is marked as the lead SNP; genes located 867 in the region are shown in the bottom. LD r^2 values are indicated by colors, and recombination 868

rates by curves. **C**) Multi-trait colocalization analysis combing six cPUFA phenotypes and BIP identified a putative shared causal variant rs174564 (PP = 0.95). PP values are shown on y axis.



Figure 4. Evidence supporting the effect of omega-6% on alcohol consumption. A) Genetic
effects of genome-wide SNPs on omega-6% (x axis) and AUDIT_C (y axis). Each dot represents
a genetic variant; colors indicate the variant density. B) MR estimated effects of omega-6% (x
axis) on AUDIT C (y axis). Effects estimated by the four models are shown by fitted lines;

876 slopes of these lines indicate the effect sizes. C) Regional association plots of five cPUFA 877 phenotypes and three alcohol consumption phenotypes in chr2:276,000,000-27,900,000. Variant 878 positions are shown on x axis, $-\log_{10}P$ on the left y axis, recombination rate on the right y axis; 879 variant rs1260326 is marked as the lead SNP; genes located in the region are shown in the bottom. LD r^2 values are indicated by colors, and recombination rates by curves. **D**) Multi-trait 880 881 colocalization analysis combing five cPUFA phenotypes and three alcohol consumption 882 phenotypes identified a shared putative causal variant rs1260326 (PP = 0.99). PP values are 883 shown on y axis.